多西他赛联合顺铂治疗晚期非小细胞肺癌的临床观察

Clinical Observation of Docetaxel Combined with Cisplatin in the Treatment of Patients with Advanced Non-Small-Cell Lung Cancer

目的观察多西他赛联合顺铂治疗晚期非小细胞肺癌(NSCLC)的疗效及安全性。方法对确诊的38例晚期NSCLC采用多西他赛联合顺铂方案化疗,21 d为1个周期,所有患者均接受不少于2个周期的化疗。化疗后评价疗效和毒副反应。结果 38例晚期NSCLC均顺利完成2个周期以上的治疗,总有效率为44.74%,中位生存期10个月。毒副反应主要为脱发、骨髓抑制、胃肠道反应和肌肉关节痛,经过对症治疗均可缓解。结论多西他赛联合顺铂治疗晚期NSCLC疗效较好,毒副反应可耐受。

Objective To evaluate the effect and safety of doeetaxel combined with eisplatin in the treatment of patients with advanced nonsmall-ceU lung cancer （NSCLC）. Methods Thirty eight patients with advanced NSCLC received doeetaxel combined with eisplatin, 21 days was a cycle. Each patient received at least two cycles. The effect and toxicities were evaluated after the treatment. Results The overall response rate was 44.74%. The median survival time was 10 months. The main toxicities were baldness, marrow suppression, gastrointestinal reaction, muscle and joint pain, and were catabatic after the symptomatic treatment. Conclusion Docetaxel combined with eisplatin is effective and safe for patients with advanced NSCLC.